SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops

SpyGlass Pharma, Inc.

97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.
Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.
100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.
Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.
Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.